HUTCHMED (China) Limited

For 2025, HUTCHMED reported total oncology revenue of $286 million, including $71 million of R&D-related upfront and milestone revenues. Net income was $457 million, driven mainly by a $416 million SHPL divestment gain; excluding that one-time item, management said core operations remained profitable. R&D expenses were $148 million. Commercially, ex-China FRUZAQLA in-market sales grew 26% year over year to $366 million, while China sales rebounded in the second half, with 21% in-market sales growth versus first-half interim results and 33% second-half growth in ELUNATE. Looking to 2026, management guided oncology revenue to $330 million to $450 million, citing continued FRUZAQLA expansion, China growth from new indications, and potential contribution from partnership opportunities and licensing income.

Johnny Cheng framed 2025 as a year of execution on the commercial portfolio and early-stage platform buildout. He emphasized the $1.4 billion cash balance as a strategic advantage that can support ATTC development, possible in-licensing, and M&A, while also keeping the company profitable. His tone was constructive and confident, highlighting multiple upcoming NDA filings, the expansion of hematology products, and a broader second wave of growth beyond the existing oncology base.

Lorenso Chiu highlighted the reported figures: $286 million in total oncology revenue, $71 million of R&D-related upfront and milestone revenue, $457 million of net income, and $148 million of R&D expense for 2025. He said expenses were lower than 2024 because many late-stage trials are nearing completion and multiple NDAs are awaiting approval, while investment is shifting toward early-stage ATTC assets. He also reiterated that cash stands at about $1.4 billion, which positions the company to accelerate ATTC development and consider external opportunities.

Analysts focused on the wide 2026 revenue guide, the timing of SAFFRON, commercial headwinds in the first half, and how investors should think about ATTC. Management said the guidance reflects a second-half recovery, growth from new indications such as RCC for ELUNATE, and continued FRUZAQLA expansion across more markets. On SAFFRON, they repeatedly said the readout is expected in mid-2026, while ATTC data are still early and no definitive timeline was given. On commercialization, management said earlier staffing was overbuilt after the GC setback, but turnover is now much lower and the team has been stabilized heading into 2026.